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Abstract: Non-peptidic RGD-mimic ligands were designed and synthesized by click chemistry between an arginine-azide mimic and an aspartic 
acid-alkyne mimic. Some of these molecules combine excellent in vitro properties (high αvβ3 affinity, selectivity, drug-like logD, high metabolic 
stability) with a variety of radiolabeling options (e.g. tritium and [18F]fluorine, plus compatibility with radio-iodination), not requiring the use of 
chelators or prosthetic groups. The binding mode of the resulting triazole RGD-mimics to αvβ3 or αIIbβ3 receptors was investigated by molecular 
modeling simulations. Compound 12 was successfully radiofluorinated and used for in vivo PET/CT studies in U87-tumour models, which 
showed only modest tumour uptake and retention, owing to rapid excretion. These results demonstrate that the novel click-RGD mimics are 
excellent radiolabeled probes for in vitro and cell-based studies on αvβ3 integrin, whereas further optimization of their pharmaco-kinetic and 
dynamic profile would be necessary for a successful use in in vivo imaging. 
Introduction 
Integrin αvβ3 is a heterodimeric transmembrane protein that belongs to the integrin superfamily receptors.[1,2] This integrin subtype 
attracted considerable attention because it plays a key role in tumour angiogenesis, growth and metastasis, and in the last two decades 
it has become an established target for tumour treatment and diagnosis.[3,4] Integrin αvβ3 is a receptor for multiple components of the 
extracellular matrix, including vitronectin, fibrinogen and fibronectin, that expose the Arg-Gly-Asp (RGD) tripeptide sequence.[5] The 
ligand-receptor recognition process is mainly regulated by the aspartic acid carboxylic group and the arginine guanidine group, both 
forming ionic interactions with a charged region of the protein.[6] These two moieties need to be separated by a 12–14 Å distance to 
allow the correct fitting into the αvβ3 binding pocket.[7] Although a number of high affinity RGD peptides have been described and some 
of them advanced to clinical trials,[8] RGD peptide mimics may offer significant advantages such as having better drug-like properties 
and allowing more flexibility in the exploration of optimized structure-activity-relationships with the receptor.[9] Structural modifications 
made on the linear pharmacophore consist of variation of the flanking amino acids and introduction of structural constraints, which were 
achieved by cyclization or by insertion of a rigid moiety (e.g. phenyl, isoxazole, 1,2,3-triazole rings and hydrazide bonds) in the flexible 
peptide sequence.[9–13] In fact, the reduction of conformational freedom towards a correct bioactive orientation favorably affects both 
activity and selectivity. From several studies focusing on the development of non-peptide RGD mimics, L-2,3-diaminopropanoic acid 
emerged as an optimal replacement of aspartic acid. Likewise, the substitution of the Arg guanidine function with less basic moieties 
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(2-aminoimidazoles, 2-aminopyridines) has been proposed.[10,11] To improve the pharmacological features of RGD peptides, a number 
of RGD peptidomimetics have been developed as therapeutic agents.[14] However, relatively few studies have investigated the use of 
these molecules as radiotracers.[15–20] Kessler and co-workers assessed the potential of non-peptidic RGD mimics as PET imaging 
agents by equipping the integrin antagonists with a bifunctional chelator (NODAGA) and labeling with 68Ga3+.[21]  More recently, the 
direct radioiodination of non-peptide integrin ligands has been reported and the resulting tracers assessed as SPECT imaging agents.[22] 
In this study we designed small-molecule RGD-mimics that combine excellent biological properties (high affinity, selectivity, suitable 
logP value) with a variety of radiolabeling options not requiring the use of chelators or prosthetic groups. To this end, a small library of 
RGD peptidomimetics was synthesized and biologically screened to identify the chemical modifications that confer the highest αvβ3 
affinity and selectivity against integrin αIIbβ3, which mediates platelet aggregation. The main features of these novel RGD mimics are: 
(a) α-N-(arylsulfonyl)-L-2,3-diaminopropanoic acid and 2-amino-3-methyl pyridine as Asp and Arg substituent, respectively; (b) a 
distance of about 13 Å between the acidic and basic groups in the predicted binding conformation; (c) a triazole ring as Gly mimetic, 
which confers favorable conformational restrictions to the linear scaffold and provides a versatile labeling site for the incorporation of 
tritium[23] and iodine[24] radioisotopes; (d) an electron-poor aromatic ring activated for 18F-labeling via nucleophilic aromatic 
substitution[25]  on the Asp-mimic portion (Figure 1). Notably, molecular modelling studies suggest that this fluorine atom may 
significantly contribute to the affinity and selectivity of these ligands through an attractive electrostatic interaction with the Tyr178 
hydroxyl group of the αv subunit.  
 
Figure 1. Structural scheme of triazole based RGD mimics with the triazole ring as labeling site for tritium or iodine radioisotopes and phenyl ring as labeling site 
for 18F. 
Results and Discussion 
Design and Synthesis. The copper-(I)-catalyzed 1,2,3-triazole cycloaddition allowed a convenient assembly of all the target 
compounds via “click chemistry” (Scheme 1). Two regioisomers (1 and 2) were initially prepared by swapping the orientation of the 
triazole ring (Figure 2). The higher affinity ligand 1 was then selected for the optimization of the biological properties and the design of 
labeled derivatives 12 and 15. 
 
  
 
Figure 2. Triazole based RGD mimic regioisomers 1 and 2 and evolution of 1 into the optimized αvβ3 ligands 12 and 15. 
 The synthesis of compound 1 and its analogues 9–16 (substituents shown in Table 1) is outlined in Scheme 1. The synthesis of 
the alkyne building blocks started from commercially available (S)-methyl-2-amino-3-(tert-butoxycarbonylamino)propanoate 
hydrochloride (3) that was reacted with arylsulfonyl chlorides 4a–d to give sulfonamides 5a–d. N-methylation of the sulfonamide function 
of 5a afforded the intermediate 5e. After acidic removal of the N-Boc protecting group from 5a–e, an amide-forming coupling was 
performed with propiolic acid, leading to the desired alkyne intermediates 6a–e. The click partners 8a–c were synthesized by alkylation 
of N-Boc protected 2-amino-3-methylpyridine 7. Coupling of alkynes 6a–e with azides 8a–c via CuAAC reaction afforded 1,2,3-triazole 
intermediates 17a–f and 17i. The iodinated 5-iodo-1,2,3-triazole analogues 17g–h were prepared by coupling alkynes 6a and 6c with 
the corresponding “click partners” 8c and 8b - respectively - in the presence of CuI, N-iodosuccinimide (NIS) and trimethylamine. 
Treatment of the methyl ester and N-Boc protected intermediates (17a–i) with LiOH followed by TFA afforded the desired products 1 
and 9–16 (for structural details see Table 1). 
 Scheme 1. Synthesis of compound 1 and its analogues (9–16). LG = Leaving Group. Reagents and conditions: (i) TEA, DCM, 12h, 0°C to room temp (78–99%); 
(ii) K2CO3, TEBA, MeI, CH3CN, 2h, room temp (85%); (iii) TFA/DCM 1:2, 2h; (iv) EEDQ, propiolic acid, DCM, 1h (50–90%); (v) NaH, K2CO3, DMF, 1.5 h (90–95%); 
(vi) CuSO4 (2%), Na ascorbate (10%), tBuOH/H2O 2:1, 12h (60–98%) ; (vii) NIS, CuI, TEA, CH3CN, 2h (45–47%) (viii) LiOH, H2O/THF 1:2, 20 min then TFA/DCM 
1:1, 2h (quantitative yields). 
The regioisomer 2 was prepared by swapping the functionalization of the “click partners” relative to 1, namely incorporating the azide 
moiety on the Asp-mimic fragment 18 and the alkyne counterpart 
on the Arg-like side chain (19). Alkyne 19 was prepared from 7 as 
already described.[23] The synthesis of the azide fragment 18 was 
accomplished by coupling of azidoacetic acid with the amine 20, 
that was prepared according to the literature.[26] “Click”-
cycloaddition of the azide 18 with the alkyne 19 gave the 1,2,3-
triazole 21. Treatment of 21 with TFA afforded the desired 
deprotected regioisomer 2 (Scheme 2). 
  
Scheme 2. Synthesis of 2. Reagents and conditions: (i) azidoacetic acid, DCC, 
DCM, 12 h (99%); (ii) CuSO4 (2%), Na ascorbate (10%), tBuOH/H2O 2:1, 12 h 
(90%); (iii) TFA/DCM 1:1, 3 h (quantitative yield). 
To investigate the possibility of radio-iodinating these RGD-
mimics, preliminary studies were performed using cold non-
radioactive conditions, applying a synthetic procedure reported by 
Årstad et al for the synthesis of imaging agents containing a 5-
[125I]Iodo-1,2,3-triazole group.[24] The click reaction between 
alkyne 6a and azide 8c was performed in the presence of a 
stoichiometric amount of CuCl2, TEA (1.5 equiv) and NaI (1 equiv). 
The reaction was monitored via LC-MS (Fig. S1 top panel, 
Supporting Information) showing the non-iodinated triazole 
analogue 17a (R, R1, R2, X = H, n=4) as the major by-product. In 
order to optimize the labeling conditions, chloramine-T (1 equiv) 
was employed as an oxidizing agent and 
tetrakis(acetonitrile)copper(I) hexafluorophosphate 
([Cu(CH3CN)4]PF6) (1 equiv) as a source of copper(I). Under 
these conditions the iodinated compound 17g (R, R1, R2 = H, X = 
I, n=4) was detected as the major peak in the HPLC 
chromatogram (see Fig. S1 bottom panel, Supporting 
Information) with no observed 17a formation. 
 
Receptor binding assays. The design of triazole containing RGD-mimics afforded a set of 10 molecules that were submitted to 
competition binding assays to determine their binding affinity toward integrin αvβ3[27] and selectivity over the closely related integrin 
αIIbβ3. Results are reported in IC50 values (Table 1). Cyclic c[RGDfK] was included in the tests as positive control in order to compare 
the new RGD mimics with a well-established rigid ligand. These tests showed that ligand length (n) has a significant impact on αvβ3 
affinity (entries 1–3), and a propyl chain (n = 3, entry 2) was found to provide the optimal distance between the Asp- and Arg-mimetic 
fragments to allow a correct fitting of the ligand into the binding pocket. Interestingly, the activity on αvβ3 and the selectivity against αIIbβ3 
seem to be strongly dependent on the substitution of the phenyl ring with fluorine and EWGs such as nitro (NO2) and trifluoromethyl 
(CF3) moieties (entries 4–6). An increased affinity (2 to 4-fold) and a remarkable improvement in selectivity (up to 36-fold) were, in fact, 
observed in this series of derivatives (compare entry 2 with 4–6).  
The IC50 values of iodinated peptidomimetics 14 and 15 compared with their non-iodinated analogues 1 and 12 revealed that 
incorporation of iodine on the triazole ring did not affect affinity and selectivity (entries 3 vs 7 and 5 vs 8). Conversely, the N-methyl 
sulfonamide derivative 16 showed a considerable drop in affinity (entry 9), confirming the crucial role that the free sulfonamide function 
-NHSO2- plays in ligand-receptor interactions. Comparison of the IC50 values of non-peptide ligands 12, 13 and 15 with that of c(RGDfK) 
Table 1. IC50 values of triazole-based RGD peptidomimetics and c(RGDfK) 
pentapeptide concerning the inhibition of c[RGDfK(Biotin-PEG-PEG)] peptide 
and biotinylated fibrinogen binding to the isolated αvβ3 and αIIbβ receptors, 
respectively. 
entry comp structure 
IC50
[a] 
αvβ3 
(nM) 
IC50
[a] 
αIIbβ3 
(nM) 
SI[c] 
1 10 
 900 ± 
8 
6090 ± 
135 
6.8 
2 9 
 
57 ± 1 
670 ± 
1 
12 
3 1 
 110 ± 
56 
500 ± 
3 
4.5 
4 11 
 
81 ± 
51 
1845 ± 
63 
23 
5 12  25 ± 3 
11690 
± 2840 
467 
6 13 
 
10 ± 3 
24400 
± 450 
2444 
7 14 
 110 ± 
34 
2450 ± 
1390 
22 
8 15 
 
10 ± 1 
6670 ± 
21 
667 
9 16 
 3600 
± 18 
- - 
10 2 
 640 ± 
12 
- - 
11 c[RGDfK] 
138 ± 
51 
20250 
± 4630 
146 
[a] IC50 values were calculated as the concentration of ligand required for 50% 
inhibition as estimated by GraphPad Prism software. Each data point is the 
average from multiple independent experiments, performed in triplicate. [b] 
Selectivity Index (SI) = IC50 αIIbβ3/ IC50 αvβ3. 
reference peptide (entry 11) indicates a considerable increase of binding affinity for αvβ3 in this series of analogues (to almost 14-fold) 
as well as an enhanced selectivity over αIIbβ3.  
Molecular Modelling. To provide structural support to biological activity data shown in Table 1, the binding mode of triazole RGD-
mimics to αvβ3 or αIIbβ3 receptors was investigated by molecular modeling simulations. Entries 1–10 were docked towards the 
crystallographic structure of each receptor,[6,28] and lowest energy poses were further relaxed by extensive energy minimization. 
 
Ligand theoretical affinity was computed by the MM-GBSA[29,30] and XSCORE[31] methods providing a very good correlation with 
experimental inhibitory activity data (R2 = 0.896 and R2 = 0.662, respectively (see also Supporting Information). Notably, the predicted 
binding mode of RGD-mimics is highly comparable with that of the crystallographic RGD ligand,[6] since they establish canonical 
interactions with the αvβ3 receptor as observed for well-known inhibitors. However, molecular docking suggested that triazole RGD-
mimics 11, 12, 13 and 15 bearing a nitro group or fluorine atoms substituted at the phenyl ring are able to form an additional H-bond 
interaction with the side chain of Tyr178 (αv subunit) (Figure 3). This interaction has never been exploited before for improving the 
affinity of integrin inhibitors and, in agreement with biological activity data of Table 1 and theoretical binding affinity (see Supporting 
Information), it may be responsible for the higher inhibitory potency against the αvβ3 receptor displayed by these molecules. Most 
notably, Try178 is missing on the αIIbβ3 receptor, where it is replaced by Phe160 that is however unable to establish H-bond interactions 
with these RGD-mimics, thus providing a structural explanation to the high selectivity for αvβ3 observed for 11, 12, 13 and 15. 
Iodine substitution is another unique feature of these triazole RGD-mimics, which was found to increase the binding affinity of 15 by 
experimental and molecular modelling studies (compare entry 5 with 8). Indeed, the iodine atom in 15, the most potent RGD-mimic of 
this series, is able to establish hydrophobic interactions with Tyr178 and Trp179 (αV) and Ala218 (β3 subunit). In contrast, iodine 
substitution in RGD-mimic 14, which bears a four-carbon linker, did not provide affinity gain, as the iodine is exposed to the solvent due 
to steric restrictions imposed by the length of the linker (compare entry 3 with 7, see also Supporting Information). 
The sulfonamide group of all molecules but 16 contacts the backbone of Asn215 and the side chain of Arg214 of the β3 subunit by H-
bonds, thus providing a rational explanation for the loss of inhibitory activity observed upon methylation of the sulfonamide NH function 
(compare entry 2 with 9).  
For additional details on binding modes and theoretical affinities see the Supporting Information. 
 
Figure 3. Predicted binding mode of RGD-mimic 15 (yellow sticks) on the crystallographic structure of αvβ3 receptor (PDB: 1L5G). αv and β3 subunits are colored 
cyan and green, respectively. Residues contacted by RGD-mimics are shown as sticks and labeled. The divalent cation in the MIDAS region is shown as a violet 
sphere. 
Labeling. Based on the affinity data discussed above, compounds 12 and 15, which are fluorinated and iodinated versions of the initial 
lead 1, represent potential radiotracers for PET and SPECT imaging. Furthermore, tritiated versions could be useful tools for in vitro 
studies. We therefore investigated the synthesis of 12 and 15 in different radiolabeled forms (tritiation and radiofluorination).  
Tritiation. Compound 12 was successfully labeled with tritium (Scheme 4). To the best of our knowledge this is the first example of 3H-
labeled non peptidic molecule able to bind integrin αvβ3, therefore [3H]12 may represent a very useful tool for in vitro or ex-vivo studies 
on angiogenesis. The palladium-mediated dehalogenation was accomplished on the 5-iodotriazole 15 employing tritium gas in a tritium 
handling manifold in the presence of Pd/C and TEA (excess) in ethanol. Complete conversion of the iodinated starting material was 
obtained after 2.5 hours and the desired product was isolated by analytical HPLC with a radiochemical purity > 99% and a specific 
activity of 469 GBq/mmol. 
  
Scheme 4. Synthesis of [3H]12. Reagents and conditions: Pd/C cat, TEA, 3H2, EtOH, 2.5 h, room temp.  
A logD (pH 7.4) = -0.55 was experimentally measured for [3H]12 (see Supporting Information for details). The compound was evaluated 
in cells that are known to express no, moderate and very high levels of αvβ3 integrin.[32,33] The magnitude of [3H]12 binding to each cell 
line was consistent with αvβ3 expression levels (Figure 4A). Non-radiolabeled c(RGDfK) (10µM) was included to competitively block 
specific binding to αvβ3. This decreased [3H]12 binding to PC3 and U87MG cells by approximately 60%, but had no effect in MCF7 cells 
(Figure 4B).  
  
Figure 4. (A) Characterization of αvβ3 expression on MCF7, PC3 and U87MG cells. Results are expressed as Median Fluorescence Intensity (MFI) of 
stained/unstained cells. (B) Cells were incubated with [3H]12 in the presence (+) or absence (-) of 10 µM c(RGDfK) peptide for 1h. [3H]12 binding is expressed as 
counts per minutes (cpm), as a function of the radioactivity added/plate and normalized for protein content. Each data point is the average ± standard deviation of 
at least three independent data points. T-test: Binding in presence vs absence of c(RGDfK) peptide; MCF7 p>0.05; PC3 p<0.001, U87MG p<0.0001. 
18F-radiolabeling. Radiolabeling of compound 12 with 18F-fluorine-was achieved via [18F]-fluoride nucleophilic substitution using the nitro 
derivative 13 as precursor (Scheme 5). 
 
Scheme 5.  
The radiosynthesis was performed as a one-pot, two-step method using the Tracerlab FX-FN platform (GE Healthcare). For the initial 
step, a [K/Kryptofix222]+ 18F- complex was prepared and dried azeotropically under a stream of helium and vacuum at 110 oC.  
 
Figure 5. Radio-RP-HPLC analysis of [18F]12 (above) and its UV profile (below). 
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Second, [18F]12 was prepared by Kryptofix-mediated [18F]nucleophilic fluorination at the nitro position of 13. Isolation of pure [18F]12 
was achieved by semi-preparative reverse phase HPLC (Fig. 5). The isolated product was then eluted through a C18 SEP-PAK to 
remove the HPLC eluent and formulated in a mixture of 0.9% saline/ethanol (92:8) for preclinical application. After radioactive decay, 
the cold [19F]12 - which had formed in the radiofluorination concomitantly with [18F]12 - was analyzed by proton-decoupled 19F-NMR 
(376 MHz) to verify the fluorination position (for a copy of the spectrum see Fig. S5, Supporting Information). A single peak at -110.1 
ppm was observed, having the same chemical shift as the fluoro group of authentic 12. The radiochemical yield (decay corrected) of 
[18F]12 from nucleophilic [18F]fluoride was 36-41% giving 2.54-2.90 GBq (n = 8) of product at the end of the radiosynthesis (EOS). The 
radiochemical purity was ≥99%, and the specific radioactivity was 248-281 GBq mol-1 (EOS). The total radiosynthesis time was 
approximately 80 min. 
 
In vivo Imaging. Promising in vitro data and successful 18F-radiolabeling prompted pilot in vivo analyses. Four mice implanted with U87 
tumour xenografts on the back were subjected to PET/CT imaging with [18F]12. Overall tumour retention of the tracer was low throughout 
the dynamic scan, whereas clearance was rapid, exhibiting both hepatobiliary and renal excretion. Uptake was initially high in the 
kidneys and liver but dropped off over the course of the 90 mins scan (Fig. 6). By 10 mins most of the injected dose could be found in 
the urinary bladder, where by 90 mins virtually all of the activity could be detected (Fig. 6 A). The low in vivo tumour uptake (0.9 ± 
0.1%ID/g) and retention of [18F]12 appears to be partly due to low bioavailability resulting in rapid excretion. The rapidity of this process 
and lack of kidney retention suggest that the molecule is excreted unchanged without any prior metabolism. This hypothesis is 
supported by human and rat liver microsomal (HLM / RLM) stability tests performed on 12, whose half-life upon incubation with HLM 
and RLM at 37 ºC in the presence of the co-factor NADPH was very high, namely 770 and 470 min, respectively, as detected by LC-
MS/MS analysis. In comparison, in similar U87-MG mouse xenograft models [18F]fluciclatide was reported to have a tumour-retention 
comprised between 1.28 ± 0.34 %ID/g and 1.88 ± 0.73 %ID/g (13 days later) 90 mins after injection. [34]  
 
Autoradiography. Sections of the U87-cells-derived tumors were mounted on slides and – after standard preparations - treated either 
directly with [18F]12 or [18F]12 incubation combined with cold 12 for determining the presence of non-specific binding. After overnight 
exposure to [18F]12 the sections treated with [18F]12 alone showed greater overall binding than the sections treated with an excess of 
cold 12 as well (Fig. 6B), indicating specific binding to αvβ3 integrin comparable to that observed in in vitro studies. Expression of integrin 
αvβ3 in the U87 tumour xenografts used was confirmed by immunohistochemical staining (see Fig. S3, Supporting Information). 
 
 
Figure 6. Time-activity curve of [18F]12 tumour uptake in U87 xenograft tumors (A).. Pre-treatment of U87 tumour sections with cold 12 (“block”) reduces [18F]12 
binding (B). C-E Time-activity curves of kidney, liver and bladder. Data in A, C -E are mean values obtained from 4 mice. Error bars indicate SD.   
Conclusions 
Novel small-molecule RGD mimics were designed and synthesized by click chemistry between an arginine-azide mimic and an aspartic 
acid-alkyne mimic. Some of these compounds displayed excellent in vitro properties (high αvβ3 affinity and selectivity, drug-like logD, 
high HLM/RLM stability), are amenable to radiolabeling with iodine, or tritium, or [18F]fluorine, and do not require the use of chelators 
or prosthetic groups. Molecular modeling simulations provided an insight into the binding mode of these compounds to αvβ3 or αIIbβ3 
receptors. Compound 12 was successfully radiofluorinated and used for in vivo PET/CT studies in U87-tumour models, which showed 
only modest tumour uptake and retention, partly owing to rapid excretion through the kidneys into urine. The results above demonstrate 
that the novel click-RGD mimics are excellent radiolabeled probes for in vitro and cell-based studies on αvβ3 integrin, whereas further 
optimization of their pharmaco-kinetic and dynamic profile will be required for a successful use in in vivo imaging via SPECT or PET/CT. 
Experimental Section 
Materials and instrumentation 
Chemicals were purchased from Sigma Aldrich and Bachem. NMR spectra were recorded using a Bruker Avance-400 spectrometer equipped with a 5 
mm single-axis Z-gradient quattro nucleus probe, operating at 376 MHz for 19F NMR. The spectrometer was operated with TOPSPIN NMR software 
(Version 2.0). Chemical shifts () are reported in parts per million (ppm), relative to trichloro-fluoro-methane (0.00 ppm).QMA SEP-PAK light cartridges 
and C18 SEP-PAK plus cartridges were obtained from Waters (Milford, MA). No-carrier-added [18F]fluoride was produced via the 18O(p, n)18F nuclear 
reaction by irradiation of a 95-97% [18O]enriched water target with a 16.4 MeV proton beam on the GE PETtrace cyclotron at the Wolfson Molecular 
Imaging Centre, Manchester, UK.  Automated synthesis of [18F]12 was carried out using the Tracerlab FX-FN radiochemistry system. Purification of 
[18F]12 by HPLC was carried out on the same system equipped with a preparative reverse phase C18 column (Prodigy ODS-Prep, 10µm particle size; 
250 x 10 mm i.d.; Phenomenex, UK). For the purpose of quality control, HPLC analysis was carried out on a Shimadzu prominence system operated 
using LabLogic software (Laura 3.0) and configured with a CBM-20A controller, LC-20AB solvent delivery system and SPD-20A absorbance detector. 
The system was equipped with a C18 Prodigy ODS(3) column, 5 µm particle size, 250 x 4.6 mm. Radioactivity was monitored with a radio-HPLC Bioscan 
Flowcount B-FC 3100 detector. 
Chemistry. 
Synthesis of 17e. Alkyne 6c (67.5 mg, 0.17 mmol, 1 equiv) and azide 8b (50 mg, 0.17 mmol, 1 equiv) were suspended in a mixture of tBuOH/H2O 2:1 
(3 mL/mmol). CuSO4 (2%) and sodium ascorbate (10%) were added and the mixture was stirred at room temperature for 12 h. The reaction mixture was 
diluted with water, extracted with ethyl acetate (30 mL) three times and washed with brine. The collected organic phases were dried over Na2SO4, filtered 
and the solvent removed under vacuum. The crude mixture was purified by preparative thin-layer chromatography (PLC) (silica gel, n-Hex/EtOAc 4:6 as 
eluent) affording 96.5 mg (83% yield) of a white solid: Rf = 0.5 (n-Hex/EtOAc 3:7); 1H NMR (400 MHz, CDCl3) δ 8.24 (s, 1H), 8.20 (d, J = 5.1 Hz, 1H), 
8.12 – 7.89 (m, 3H), 7.43 (s, 1H), 7.20 (t, J = 9.2 Hz, 1H), 6.89 – 6.84 (m, 2H), 4.49 (t, J = 7.1 Hz, 2H), 4.34 – 4.26 (m, 1H), 3.99 (t, J = 6.7 Hz, 2H), 3.91 
– 3.72 (m, 2H), 3.65 (s, 3H), 2.43 – 2.21 (m, 5H), 1.50 (s, 9H); 19F NMR (376 MHz, CDCl3) δ -61.74 (d, J = 12.5 Hz), -107.17 (q, J = 12.5 Hz); 13C NMR 
(101 MHz, CDCl3) δ 170.1, 161.7 (d, J = 262.3 Hz), 161.0, 154.2, 153.9, 148.5, 147.2, 142.1, 137.2 (d, J = 3.8 Hz), 133.3 (d, J = 9.8 Hz), 126.9, 126.2, 
121.6 (q, J = 273.3 Hz), 121.1, 119.9, 118.9 (dd, J = 34.0, 13.5 Hz), 117.9 (d, J = 21.8 Hz), 81.6, 56.2, 52.9, 48.7, 43.9, 41.2, 29.3, 28.3, 21.1; MS (ESI, 
m/z): C28H34F4N7O7S [M+H]+ calc. 688.21 found 688.2. [α]D25 = -3 (c = 0.7, CHCl3). 
Synthesis of 12. The methyl ester and N-Boc diprotected intermediate 17e (91 mg, 0.13 mmol) was dissolved in THF (0.2 M) and a solution of LiOH 4 
M in water (500 μL/mmol) was added. The reaction mixture was vigorously stirred at r.t. After cleavage of the methyl ester function (20 min) the THF was 
removed in vacuo and the reaction mixture was partitioned between DCM and HCl (1 M aq.). The organic layer was dried over Na2SO4 and concentrated 
under low pressure. The resulting colourless oil was dissolved in a solution of TFA/DCM 1:1 and stirred for 2 h at r.t. for removal of the Boc protecting 
group. The solution was concentrated bubbling nitrogen into the flask and then lyophilized. After lyophilisation the product appeared as a white solid (90 
mg, quantitative yield, MW = 12 · 1 TFA = 573.5 + 114 = 687.5): 1H NMR (400 MHz, CD3OD) δ 8.37 (s, 1H), 8.16 – 8.12 (m, 2H), 7.73 (d, J = 6.6 Hz, 
1H), 7.44 (t, J = 9.9 Hz, 1H), 6.86 (s, 1H), 6.80 (dd, J = 6.7, 1.4 Hz, 1H), 4.63 (t, J = 6.8 Hz, 2H), 4.30 (dd, J = 8.8, 4.9 Hz, 1H), 3.81 (dd, J = 13.8, 4.9 
Hz, 1H), 3.55 (dd, J = 13.8, 8.9 Hz, 1H), 3.42 (t, J = 6.8 Hz, 2H), 2.43 (s, 3H), 2.40 – 2.31 (m, 2H); 19F NMR (376 MHz, CD3OD) δ -63.20 (d, J = 12.7 Hz), 
-76.97, -110.65 (q, J = 12.7 Hz); 13C NMR (101 MHz, DMSO) 171.4, 160.2, 161.0 (d, J = 260.0 Hz), 158.61, 153.2, 142.7, 138.63 (d, J = 3.6 Hz), 136.5, 
134.26 (d, J = 10.5 Hz), 127.0, 126.5, 122.2 (q, J = 273.4 Hz), 118.78 (d, J = 21.8 Hz), 117.51 (dd, J = 33.4, 13.4 Hz), 114.6, 111.8, 55.7, 47.7, 40.5 
(signal detected by HSQC as it overlaps with solvent peak), 39.5 (partially overlaps with solvent peak), 28.9, 21.8; HRMS (ESI, m/z): C22H24F4N7O5S 
[M+H]+ calc. 574.14 found 574.1475. [α]D25 = +5 (c = 1.3, DMSO). 
Flow cytometry analysis of αvβ3 integrin expression 
Cells were seeded at 0.35 x 106 cells/60 mm plate and grown for 72 h before the experiment. Cells were harvested from plates using cell dissociation 
reagent. αvβ3 cell surface expression was determined by flow cytometry as previously described,[33] using the LM609 antibody which binds selectively to 
αvβ3 integrin and detected with an Alexa Fluor 488 secondary antibody. Results are expressed as Median Fluorescence Intensity (MFI) of stained/ 
unstained cells (i.e. fluorescence in the presence/absence of αvβ3 antibody). 
Radiotracer binding assays 
Binding assays were performed as described in the literature.[27,33] 
Automated synthesis of [18F]12 
The automated synthesis of [18F]12 was carried out on the TRACERlab FX-FN radiochemistry system as follows. No-carrier-added [18F]fluoride was 
delivered to the system and passed through a QMA SEP-PAK light cartridge where the [18F]fluoride was trapped and [18O]water collected for recycling. 
Trapped [18F]fluoride was eluted off the cartridge with a solution of Kryptofix 2.2.2 (K222)/0.1M K2CO3/ACN (1 mL) into a reaction vessel. The mixture 
was azeotropically dried under a stream of helium and vacuum at 110o C for 4 min. The drying step was repeated with acetonitrile (1 mL) then compound 
13 (2.0 mg) in anhydrous DMSO (1.0 mL) was added and the reaction mixture heated at 120o C for 20 min. At the end of the reaction a 1 mL mixture of 
ACN/water (35/65, v/v; 0.01% TFA) was added and the entire sample loaded onto a C18 Prodigy ODS-Prep column (10µm particle size; 250 x 10 mm) 
eluted with ACN/water (35/65, v/v; 0.01% TFA) at a flow rate of 3 mL/min. Eluate from the column was monitored for radioactivity and UV absorbance at 
320 nm. The fraction containing [18F]12 was collected in a round bottom flask containing water (40 mL) (Figure X) and the resultant mixture passed 
through a C18 SEP-PAK plus cartridge. The cartridge was rinsed with water (10 mL) and the product eluted with sterile ethanol (1 mL) and collected in 
sterile 0.9% saline (10 mL). Finally, the product was dispensed into a sterile vial via a 0.2 micron sterile filter for preclinical application. The radiochemical 
purity of the product was determined by HPLC using a C18 Prodigy ODS (3) column (5 µm particle size; 250 x 4.6 mm) eluted with ACN/water (35/65, 
v/v; 0.01% TFA) at a flow rate of 2 mL/min. The retention time for [18F]12 was 8.6 min. 
PET/CT imaging.  
Four female cba nu/nu mice were implanted with 0.1mL of a 5x107/mL suspension of U87 cells i/d on the back. Tumors were measured daily once since 
a palpable tumour became apparent. Once tumors reached approx. 500mm3, PET scans were performed to assess [18F]12 tracer uptake and 
biodistribution. Mice were anaesthetized by placing in an induction chamber and turning the isofluorane to 2% (oxygen at 2L/min). Mice were transferred 
to an anesthetic facemask on a heated bed and settled for 5 minutes and the tail vein dilated and catheterized. Mice were then transferred to the 
temperature-controlled imaging bed and attached to the anesthetic facemask. After CT scanning, 10-15MBq [18F]12  in a total volume < 200µL was 
injected i/v. Imaging  commenced immediately after tracer injection, during which time body temperature and depth of anesthesia were monitored using 
readouts from the imaging bed. At the end of PET scanning, the mice will be removed from the scanner and sacrificed. Tumors were excised and 
sectioned for autoradiography and immunohistochemistry. Inveon acquired data: before reconstruction, the list-mode data were histogrammed with a 
span of 3 and maximum ring differences of 79 into 3D sinograms with 19 time frames (5 × 60 seconds (s), 5 × 120s, 5×300s and 4 × 300s) for image 
reconstruction. Images were reconstructed using the 3D-OSEM/MAP algorithm (4 OSEM3D iterations and no MAP iterations, with a requested resolution 
of 1.5mm). Regions of interest (ROIs) were drawn manually over tumors using Inveon Research Workplace software (Siemens, Germany) and further 
normalization was performed using the injected dose (from the dose calibrator) and animal weight to give a standardized uptake value (SUV). SUVmax 
was calculated from the maximum voxel value within the ROI and SUVmean as the average over all voxels. 
Autoradiography 
Sections of flash-frozen U87 tumors cut at 20m on a cryotome and mounted on slides were pre-incubated in Tris-NaCl at 4oC for 5 mins. The slides 
were then incubated for 1 hour in Tris-NaCl plus ligands at room temp (50MBq of [18F]12 in 50mL Tris-NaCl in both, plus 2 mL of 100ug/mL cold [18F]12 
for non-specific binding test). The slices were rinsed with 2x5 mins in Tris-NaCl at 4oC, then quickly rinsed in H2O at 4oC. Slides were prepared for 
phosphor-imager (FujiFilm BAS-1800 II) and exposed overnight. 
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